

Management Change - Update

Melbourne, Australia – 7 March 2025: Adherium Limited (ASX:ADR)

Further to the Company's ASX announcement of 30 October 2024 and the update in our half yearly report filed on 28 February 2025 – Dr Mastoridis has now issued proceedings in New Jersey court under the New Jersey Conscientious Employee Protection Act.

The Company denies Dr Mastoridis' claims and intends to continue to strenuously contest them.

For more information about Adherium and its revolutionary respiratory solutions, please visit adherium.com.

- ENDS -

This ASX announcement was approved and authorised for release by the Board of Adherium.

Investor Enquiries

Daniel Kaplon
Adherium Limited
Chief Financial Officer
investors@adherium.com

Media Enquiries:

Haley Chartres
HACK
Director
haley@hck.digital

About Adherium (ASX: ADR)

Adherium is a provider of integrated digital health solutions and a worldwide leader in connected respiratory medical devices. Adherium's Hailie® platform solution provides clinicians, healthcare providers and patients access to remotely monitor medication usage parameters and adherence, supporting reimbursement for qualifying patient management. The Hailie® solution includes a suite of integration tools to enable the capture and sharing of health data via mobile and desktop apps, Software Development Kit (SDK) and Application Programming Interface (API) integration tools, and Adherium's own broad range of sensors connected to respiratory medications. Adherium's Hailie® solution is designed to provide visibility to healthcare providers of medication use history to better understand patterns in patient respiratory disease.

Learn more at adherium.com